Anaptys Royalty Co https://validator.w3.org/feed/docs/rss2.html Daniel Faga Home First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement Global Privacy Policy Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations Our Partnerships Key Catalysts Financials John Schmid Hollings Renton John Orwin Oleg Nodelman Susannah Gray Financial Collaborations About Us Luisa Salter-Cid, PH.D. Dolor sit amet – consectetur adipiscing Why amet lorem dolor glavrida agestas John G. Monroe, Ph.D. Dolca Thomas, M.D. Eric Loumeau, J.D. Daniel Faga CFO Ben Stone Christopher Hunter, Ph.D. Terms of Use